Last reviewed · How we verify
Microcrystalline Methylcellulose
At a glance
| Generic name | Microcrystalline Methylcellulose |
|---|---|
| Sponsor | Dr. Rachel Holden |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of Daily Humiome® Post LB Intake on Wellbeing in Older Individuals With Moderate Stress Levels (NA)
- A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis (PHASE3)
- Psilocybin for Major Depressive Disorder (MDD) (PHASE3)
- Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old (PHASE3)
- Effect of ExoBDNF Lactic Acid Bacteria Supplement on Cognitive Functions, Sleep and Psychological (NA)
- Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients (PHASE2)
- A Study to Evaluate a Postbiotic in Supporting Weight Loss and Metabolic Health (NA)
- Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Microcrystalline Methylcellulose CI brief — competitive landscape report
- Microcrystalline Methylcellulose updates RSS · CI watch RSS
- Dr. Rachel Holden portfolio CI